BridgeMD
New treatment option for Schizophrenia and Related Disorders
Official title rTMS for Depressive, Positive and Negative Symptoms, and Physiological Indices of Schizophrenia Patients
ClinicalTrials.gov ID: NCT05671185
What this study is testing
- What it's testing
- Around 40% of schizophrenia patients present depressive symptoms, which are associated with elevated suicide and violence risk and poor prognosis and quality of life. Recent meta-analysis showed the effect size of antidepressants for depressive symptoms of schizophrenia patients was as low as 0.25, so new therapeutic approach is warranted.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 and older
You may be able to join if
- Age ≥ 20 years
- Able to give informed consent
- Diagnosed with schizophrenia or schizoaffective disorder according to DSM-5
- Has a score ≥ 7 on Calgary depression scale for schizophrenia
- The principal psychotropic agents are not changed within one month of the first session of rTMS
You likely can't join if
- DSM-5 defined substance use disorder (excluding tobacco) in the past 3 months
- Have clinically relevant cognitive impairment (e.g., delirium, intellectual disability or MMSE \< 15)
- With electronic and/or magnetic implants (e.g. pacemaker, implantable cardioverter defibrillator [ICD], cerebral shunts, cochlear implant, etc.)
- With metallic or mechanic fragments (e.g., screws, plates, stents, clips, etc.)
- Pregnant, or has a pregnancy plan within 3 months
- With any known or history of neurological conditions including cerebral vascular accidents, epilepsy (or epileptiform waves detected by EEG prior to...
See the full eligibility criteria
- Age ≥ 20 years
- Able to give informed consent
- Diagnosed with schizophrenia or schizoaffective disorder according to DSM-5
- Has a score ≥ 7 on Calgary depression scale for schizophrenia
- The principal psychotropic agents are not changed within one month of the first session of rTMS
- DSM-5 defined substance use disorder (excluding tobacco) in the past 3 months
- Have clinically relevant cognitive impairment (e.g., delirium, intellectual disability or MMSE \< 15)
- With electronic and/or magnetic implants (e.g. pacemaker, implantable cardioverter defibrillator [ICD], cerebral shunts, cochlear implant, etc.)
- With metallic or mechanic fragments (e.g., screws, plates, stents, clips, etc.)
- Pregnant, or has a pregnancy plan within 3 months
- With any known or history of neurological conditions including cerebral vascular accidents, epilepsy (or epileptiform waves detected by EEG prior to the first session of rTMS), brain tumor or space occupying lesion
- Received rTMS or iTBS treatment within 3 months
- Has a clinically significant abnormality on the screening examination that might affect safety, study participation, or confound interpretation of study results
The study team makes the final eligibility decision.
Where it's taking place
- Douliu, Yunlin, Taiwan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 20 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Douliu, Yunlin, Taiwan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.